All In Biotech

Drug Trial Radar · NCT07480785

TEAS Combined With Triple Antiemetic Drugs to Prevent PONV in High-Risk Patients

Transcutaneous Electrical Acupoint Stimulation Combined With Triple Antiemetic Drugs for Postoperative Nausea and Vomiting in High-Risk Patients: A Multicenter Randomized Controlled Trial

Last checked: Nov 20, 2026Latest source record: Mar 18, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 780 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

780

Planned (sponsor's estimate)

Start

Jan 16, 2026

Primary completion

Oct 31, 2027

Study completion Oct 31, 2027

Sponsor

Lead sponsor
Zhejiang UniversityAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Jinhua Central Hospital; Huzhou Central Hospital; The First People's Hospital of Huzhou
First posted
Mar 18, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable
Allocation
Randomized
Model
Parallel
Masking
Double (participant, outcomes assessor)
Primary purpose
Prevention
FDA-regulated drug
No
Who can join
Female only, from 18 years, up to 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The goal of this clinical trial is to evaluate the effects of transcutaneous electrical acupoint stimulation (TEAS) combined with triple antiemetics for postoperative nausea and vomiting (PONV) in high-risk patients. The primary question it seeks to answer is: Does TEAS combined with triple antiemetics further reduce the incidence of PONV in high-risk subjects? Researchers will compare active TEAS with sham stimulation to determine whether the addition of TEAS to dexamethasone, palonosetron, and droperidol lowers the PONV rate beyond that achieved by the triple-drug prophylaxis alone.

Conditions

  • Uterine Fibroids (Leiomyoma)
  • Ovarian Tumors
  • Gallstones

Interventions

  • transcutaneous electrical acupoint stimulationDevice

    Using the Huatuo brand electronic acupuncture therapy device (Model: SDZ-Ⅲ, produced by Suzhou Medical Equipment Co., Ltd., China), bilateral upper limb acupoints P6+L14 were selected. Approximately 30 minutes before anesthesia induction, the electrodes were connected with the initial current set at 1 milliampere and frequency at 2/100 Hz. The current intensity was gradually increased until the patient felt pain or reached the discomfort threshold (ranging between 6 to 10 mA), and the stimulation was maintained until the patient was discharged from the PACU.

  • Sham transcutaneous electrical acupoint stimulationDevice

    The same protocol was applied for percutaneous acupoint electrical stimulation, initiated before anesthesia induction with the minimum perceptible current (MPC) and terminated after 1 minute.

  • triple antiemetic drugsDrug

    Dexamethasone 5mg and palonosetron 0.25mg i.v. will be given after induction, and droperidol 1.25 mg i.v. will be given during the abdominal closure.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants Experiencing Nausea,Retching and Vomiting within 24 hours after operation.Time frame: 2 hours post-operation, 6 hours post-operation, 24 hours post-operation

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • The First Affiliated Hospital, Zhejiang University School of Medicine

    Hangzhou, Zhejiang, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.